Mayukh Sukhatme Sells 284,707 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) insider Mayukh Sukhatme sold 284,707 shares of the business’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $36.25, for a total value of $10,320,628.75. Following the completion of the sale, the insider owned 18,630,739 shares in the company, valued at $675,364,288.75. This represents a 1.51% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Mayukh Sukhatme also recently made the following trade(s):

• On Friday, August 14th, Mayukh Sukhatme sold 243,177 shares of Roivant Sciences stock. The shares were sold at an average price of $36.23, for a total transaction of $8,810,302.71.
• On Tuesday, August 18th, Mayukh Sukhatme sold 136,942 shares of Roivant Sciences stock. The shares were sold at an average price of $36.73, for a total transaction of $5,029,879.66.

Roivant Sciences Stock Performance

Shares of Roivant Sciences stock traded up $1.13 during trading hours on Tuesday, reaching $37.37. 6,409,504 shares of the company were exchanged, compared to its average volume of 5,396,372. Roivant Sciences Ltd. has a 1 year low of $11.54 and a 1 year high of $37.46. The stock’s fifty day moving average is $34.16 and its 200 day moving average is $30.17. The firm has a market cap of $26.99 billion, a PE ratio of -70.51 and a beta of 1.12.

Roivant Sciences (NASDAQ:ROIV) last released its earnings results on Friday, August 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. The firm had revenue of $1.44 million during the quarter, compared to analyst estimates of $2.06 million. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%. Research analysts expect that Roivant Sciences Ltd. will post -1.83 earnings per share for the current year.

Analysts Set New Price Targets

ROIV has been the topic of a number of recent analyst reports. Sanford C. Bernstein raised shares of Roivant Sciences to a “strong-buy” rating in a research report on Wednesday, July 29th. TD Cowen reissued a “buy” rating on shares of Roivant Sciences in a report on Thursday, August 6th. Bank of America reaffirmed a “neutral” rating on shares of Roivant Sciences in a report on Friday, July 31st. Citigroup increased their price objective on Roivant Sciences from $42.00 to $46.00 and gave the company a “buy” rating in a report on Monday, August 10th. Finally, Leerink Partners set a $42.00 target price on Roivant Sciences in a research note on Thursday, May 21st. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Roivant Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $35.14.

Institutional Trading of Roivant Sciences

Large investors have recently bought and sold shares of the business. SBI Securities Co. Ltd. grew its holdings in shares of Roivant Sciences by 1,740.3% during the fourth quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock worth $27,000 after buying an additional 1,166 shares during the last quarter. Allworth Financial LP lifted its holdings in shares of Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after purchasing an additional 583 shares during the period. Kestra Advisory Services LLC acquired a new stake in shares of Roivant Sciences during the fourth quarter worth $47,000. Parallel Advisors LLC grew its position in Roivant Sciences by 33.7% in the 1st quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock valued at $57,000 after buying an additional 520 shares during the last quarter. Finally, CIBC Private Wealth Group LLC increased its stake in Roivant Sciences by 7,614.3% in the 4th quarter. CIBC Private Wealth Group LLC now owns 2,700 shares of the company’s stock valued at $59,000 after buying an additional 2,665 shares during the period. Institutional investors and hedge funds own 64.76% of the company’s stock.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.